Search

Search Results
Results 25731 - 25740 of 25856 for AIDS
  • Interleukin-4 receptor (IL-4R): A drug target with massive potential
    White Paper - 30 Aug 2022
    The interleukin-4 receptor (IL-4R) is emerging as a potential drug target, projected to potentially be worth up to 10 billion USD. In this article, ACROBiosystems discusses why it is such an...
  • VEGF: A consistent target for antitumor therapy
    White Paper - 30 Aug 2022
    In this article, ACROBiosystems discusses Vascular Endothelial Growth Factor (VEGF) and its enduring use as a target in antitumor therapy.
  • Glivec Tablets
    Drug - 3 Aug 2022
    Consumer Medicine Information (CMI) about Glivec Tablets intended for persons living in Australia.
  • DBL Pentamidine Isethionate
    Drug - 20 Jun 2022
    Consumer Medicine Information (CMI) about DBL Pentamidine Isethionate intended for persons living in Australia.
  • Combating Parkinson’s disease, the second most common neurodegenerative disease
    White Paper - 30 May 2022
    Parkinson’s disease is the second most common neurodegenerative disease. As it continues to affect more and more people, there’s massive demand for continued and new research into novel and...
  • Zykadia
    Drug - 5 Apr 2022
    Consumer Medicine Information (CMI) about Zykadia intended for persons living in Australia.
  • Analysis of additives in diet soft drinks with green chemistry
    White Paper - 23 Feb 2022
    Discover more about the analysis of additives in diet soft drinks with green chemistry.
  • Lorviqua
    Drug - 23 Dec 2021
    Consumer Medicine Information (CMI) about Lorviqua intended for persons living in Australia.
  • Navelbine IV
    Drug - 17 Dec 2021
    Consumer Medicine Information (CMI) about Navelbine IV intended for persons living in Australia.
  • Navelbine Oral
    Drug - 17 Dec 2021
    Consumer Medicine Information (CMI) about Navelbine Oral intended for persons living in Australia.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback